Antitumor effects of a human dimeric antibody fragment 131I- AFRA-DFM5.3 in a mouse model for ovarian cancer

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1938-1946

  Zacchetti, Alberto ^a   Martin, Franck ^b   Luison, Elena ^a   Coliva, Angela ^a   Bombardieri, Emilio ^a   Allegretti, Marcello ^b   Figini, Mariangela ^a   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Chemistry Section   (Italy)

Author keywords

Experimental radioimmunotherapy; Folate receptor; Human antibody fragment; Ovarian cancer

Indexed keywords

AFRA DFM; AFRA DFM5.3 I 131; CANCER ANTIBODY; FOLATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; OVARIAN NEOPLASMS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RADIOIMMUNOTHERAPY;

EID: 83755168279     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086819     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol. 2010;119:151-156.
3. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-327.
4. Figini M, Martin F, Ferri R, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother. 2009;58:531-546.
5. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24:539-567. (Pubitemid 43097000)
6. Knogler K, Grunberg J, Zimmermann K, et al. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res. 2007;13:603-611. (Pubitemid 46225367)
7. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122-135.
8. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-357.
9. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053-1064.
10. Singhal P, Lele S. Intraperitoneal chemotherapy for ovarian cancer: where are we now? J Natl Compr Canc Netw. 2006;4:941-946. (Pubitemid 44580193)
11. 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686-690.
12. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
13. Canevari S, Mezzanzanica D, Mazzoni A, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother. 1995;4:423-427.
14. Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR Jr. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 1994;54:2448-2455. (Pubitemid 24138739)
15. Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med. 1992;33:2000-2005.
16. Buist MR, Kenemans P, Den Hollander W, et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab′)2 fragments in ovarian carcinoma patients. Cancer Res. 1993;53:5413-5418. (Pubitemid 23342159)
17. Buijs WCAM, Massuger LFAG, Claessens RAMJ, Kenemans P, Corstens FHM. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. J Nucl Med. 1992;33:1113-1120.
18. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer. 2001;92:106-114. (Pubitemid 32187039)
19. Figini M, Obici L, Mezzanzanica D, et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res. 1998;58:991-996. (Pubitemid 28182469)
20. 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol. 2009;36:759-770.
21. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200-1213.
22. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555-1577.
23. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127-1135.
24. Kobayashi H, Le N, Kim IS, et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999;59:422-430. (Pubitemid 29048878)
25. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115S-127S. (Pubitemid 47619027)
26. 211At-MX35 F(ab′)2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006;33:1065-1072.
27. Dearling JL, Pedley RB. Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol). 2007;19:457-469. (Pubitemid 46995619)
28. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer. 1995;61:557-566.
29. Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumour Biol. 1997;18:367-377. (Pubitemid 27475717)
30. Blumenthal RD, Taylor A, Osorio L, et al. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer. 2001;94:564-571.
31. Miotti S, Canevari S, Ménard S, et al. Characterization of human ovarian carcinoma- associated antigens defined by novel monoclonal antibodies with tumorrestricted specificity. Int J Cancer. 1987;39:297-303. (Pubitemid 17038183)
32. Stein R, Goldenberg DM, Mattes MJ. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer. 1991;47:163-169.
33. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
34. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74:193-198. (Pubitemid 27234510)
35. Ottone F, Miotti S, Bottini C, et al. Relationship between folate binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer. 1997;76:77-82. (Pubitemid 27250079)
36. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010;10:431-437.